There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VCAM-1


VCAM-1 Molecule Information

Name:Vascular Cell Adhesion Molecule 1
Target Synonym:CD_antigen=CD106;L1CAM;VCAM1;V-CAM 1;INCAM-100;VCAM-1;Vascular cell adhesion protein 1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

VCAM-1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VC1-H5224 Human Human VCAM-1 / CD106 Protein, His Tag

VCAM-1 Part of Bioactivity data

Human VCAM-1, His TagHuman VCAM-1, His Tag (Cat. No. VC1-H5224) ELISA bioactivity

Immobilized Human VCAM-1, His Tag (Cat. No. VC1-H5224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 0.01-0.156 μg/mL (QC tested).

VCAM-1 Molecule Synonym Name


VCAM-1 Molecule Background

Vascular cell adhesion protein 1 (VCAM1) is also known as CD106, INCAM-100 and L1CAM, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. VCAM1 / CD106 contains 7 Ig-like C2-type (immunoglobulin-like) domains. CD106 / VCAM-1 is expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue. L1CAM / VCAM-1 is Important in cell-cell recognition and appears to function in leukocyte-endothelial cell adhesion. CD106 / VCAM1 interacts with the beta-1 integrin VLA4 on leukocytes, and mediates both adhesion and signal transduction. The VCAM1 / VLA4 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. INCAM-100 / VCAM1 binds to ECMV-D capsid proteins and acts as a receptor for this virus.

VCAM-1 References

VCAM-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocopherol acetate DSE-9912 Approved Unknown Venous thromboembolism (VTE), Intermittent claudication, Diabetic retinopathy, Prevention of atherothrombotic events, Thrombosis Details

VCAM-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
FG-4497 FG-4497,FG 4497; FG4497 Preclinical FibroGen Psoriasis, Arthritis Details
Elsibucol AGI-1096,AGI1096 Phase Ⅰ AtheroGenics, Astellas Rejection of organ transplantation Details
DZ-13 DZ-13; DZ13 Phase Ⅰ University of New South Wales, Royal Prince Alfred Hospital Basal cell carcinoma (BCC), Metastatic melanoma Details

This web search service is supported by Google Inc.